ASR Vermogensbeheer N.V. Acquires Shares of 1,893 Bio-Rad Laboratories, Inc. (NYSE:BIO)

Key Points

• ASR Vermogensbeheer N.V. acquired a new position in Bio-Rad Laboratories, purchasing 1,893 shares valued at approximately $461,000.
• Several institutional investors, including Bank of America and GAMMA Investing LLC, have significantly increased their holdings in Bio-Rad, reflecting strong investor interest.
• Bio-Rad reported a net margin of 12.50% and a revenue increase of 2.1% year-over-year, with analysts anticipating 10.81 earnings per share for the current year.

ASR Vermogensbeheer N.V. purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,893 shares of the medical research company's stock, valued at approximately $461,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. XTX Topco Ltd boosted its stake in Bio-Rad Laboratories by 134.3% in the first quarter. XTX Topco Ltd now owns 4,567 shares of the medical research company's stock valued at $1,112,000 after acquiring an additional 2,618 shares during the last quarter. Federated Hermes Inc. boosted its stake in Bio-Rad Laboratories by 2.0% in the first quarter. Federated Hermes Inc. now owns 140,250 shares of the medical research company's stock valued at $34,159,000 after acquiring an additional 2,689 shares during the last quarter. Mawer Investment Management Ltd. raised its position in shares of Bio-Rad Laboratories by 14.8% in the first quarter. Mawer Investment Management Ltd. now owns 294,879 shares of the medical research company's stock valued at $71,821,000 after purchasing an additional 37,952 shares during the period. Mackenzie Financial Corp raised its position in shares of Bio-Rad Laboratories by 161.8% in the first quarter. Mackenzie Financial Corp now owns 1,647 shares of the medical research company's stock valued at $401,000 after purchasing an additional 1,018 shares during the period. Finally, LPL Financial LLC raised its position in shares of Bio-Rad Laboratories by 3.4% in the first quarter. LPL Financial LLC now owns 5,374 shares of the medical research company's stock valued at $1,309,000 after purchasing an additional 179 shares during the period. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Trading Up 3.8%

BIO traded up $9.96 during trading on Tuesday, hitting $274.49. 235,138 shares of the stock traded hands, compared to its average volume of 338,485. The firm has a market capitalization of $7.43 billion, a P/E ratio of 23.40 and a beta of 0.90. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.12 and a quick ratio of 3.67. The firm has a 50-day moving average of $247.31 and a 200 day moving average of $256.42. Bio-Rad Laboratories, Inc. has a 12-month low of $211.43 and a 12-month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical research company reported $2.61 EPS for the quarter, topping the consensus estimate of $1.93 by $0.68. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The business had revenue of $651.60 million during the quarter, compared to analyst estimates of $614.82 million. During the same period in the prior year, the business earned $3.11 EPS. The company's revenue for the quarter was up 2.1% on a year-over-year basis. Equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on BIO shares. Wall Street Zen raised shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Royal Bank Of Canada upped their target price on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. Wells Fargo & Company upped their target price on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Citigroup decreased their target price on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Finally, UBS Group decreased their target price on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $333.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.